Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Network Modeling Predicts How DYRK1A Inhibition Promotes Cardiomyocyte Cycling After Ischemic/Reperfusion Injury

ABSTRACT: The adult mammalian heart has a limited ability to regenerate lost myocardium following myocardial infarction (MI), largely due to the poor proliferative capacity of cardiomyocytes (CMs). Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is a known regulator of cell quiescence, though the mechanisms underlying its function remain unclear. Previous studies have shown that pharmacological inhibition of DYRK1A using harmine induces CM cell cycle re-entry after ischemia/reperfusion (I/R) MI. Here, we developed a computational network model of DYRK1A-mediated regulation of the cell cycle, which predicts how DYRK1A inhibition promotes CM re-entry. To validate these predictions, we tested selective DYRK1A inhibitors and observed robust induction of cell cycle activity in neonatal rat cardiomyocytes (NRCMs). Integrating our network model with bulk RNA-sequencing data from DYRK1A inhibitor-treated NRCMs, we identified E2F1 as a key transcriptional driver of cell cycle gene expression. Finally, we demonstrate that both pharmacological and post-developmental inhibition of DYRK1A enhances heart function and increases CM cycling following I/R MI. Our findings suggest that functional recovery induced by small molecule inhibitor of DYRK1A is mediated by the induction of cycling CMs.

ORGANISM(S): Rattus norvegicus

PROVIDER: GSE341619 | GEO | 2026/09/03

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

RNAseq of a unique human heart 5 days post-myocardial infarction versus healthy donor controls

Project description:Background: Myocardial infarction (MI) is a leading cause of death worldwide and can eliminate up to a third of the cardiomyocytes (CMs) within the human heart. Although CMs undergo mitosis during early development, most CMs cease cell cycling soon after birth. In contrast, rodent MI models have shown that CMs increase mitosis in response to ischemia, however this has not been shown in humans. Methods: Using a unique pre-mortem post-MI human heart, immunostaining, bulk RNA sequencing, proteomics, metabolomics, single nucleus RNA sequencing and a novel post-MI human biopsy method, we investigated human CM mitosis post-MI. Results: We show that adult human CMs exhibit increased mitosis and cytokinesis in response to ischemia. Conclusions: Future development of therapeutics to enhance this intrinsic mitotic potential could lead to new treatments that reverse heart failure via cardiac regeneration. This dataset is the bulk RNAseq dataset relating to a unique infarcted heart - left ventricle (6004 LV), right ventricle (6004 RV), right atrium (6004 RA) and healthy donor left ventricle (donor LV).

2025-12-31 | E-MTAB-16453 | biostudies-arrayexpress

Pharmacological or genetic inhibition of LTCC promotes cardiomyocyte proliferation through inhibition of calcineurin activity

Project description:Cardiomyocytes (CMs) lost during ischemic cardiac injury cannot be replaced due to their limited proliferative capacity. Ca2+ is an important signal transducer that regulates key cellular processes, but its role in regulating CM proliferation is incompletely understood. A drug screen targeting proteins involved in CM Ca2+ cycling in human embryonic stem cell-derived cardiac organoids (hCOs) revealed that only the inhibition of L-Type Calcium Channel (LTCC) using nifedipine induced the CM cell cycle. Overexpression of Ras-related associated with Diabetes (RRAD), an endogenous inhibitor of LTCC, induced CM cell cycle activity in vitro, in human cardiac slices, and in vivo. Mechanistically, LTCC inhibition by RRAD or nifedipine induced CM cell cycle by modulating calcineurin activity and Hoxb13 nuclear translocation. Moreover, ectopic expression of RRAD/CDK4/CCND in combination induced CM proliferation in vitro and in vivo, improved cardiac function and reduced scar size post-myocardial infarction. Together, these findings represent a robust pathway for new Ca2+ signaling-based cardiac regenerative strategies.

2025-01-15 | GSE270406 | GEO

TGF-β Signalling Drives Chemotaxis of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Response to MI Stimulus

Project description:Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) hold significant promise for cardiac regeneration therapies. However, the efficacy of such treatments depends on the ability of transplanted cells to migrate and integrate into the damaged myocardium, a process that remains poorly understood. In this study, we investigated the migratory behaviour of hiPSC-CMs using homogenised rat MI tissue to simulate myocardial infarction (MI) in vitro. Transwell migration assays demonstrated a concentration-dependent chemotactic response, with hiPSC-CM migration increasing up to threefold toward MI tissue homogenate. Wound healing assays further confirmed enhanced migration under MI-mimetic conditions. Bulk RNA sequencing revealed activation of the TGF-β signalling pathway as a key regulator of this response. Inhibition of TGF-β signalling, both pharmacologically and through antibody neutralisation, significantly reduced hiPSC-CM migration. These findings uncover a previously underappreciated chemotactic capability of hiPSC-CMs and identify TGF-β signalling as a central mediator, offering new mechanistic insights and potential therapeutic targets to improve the integration and efficacy of hiPSC-CM-based cardiac regeneration strategies.

2026-01-31 | GSE317615 | GEO

Identifying transcription factors distinguishing regenerating cardiomyocytes in the zebrafish heart using single cell transcriptomics

Project description:Zebrafish hearts present a remarkable regenerative capacity upon injury, constituting a valuable source of information for cardiomyocyte (CM) cycle re-entry/proliferation. Understanding which factors contribute for zebrafish heart regeneration is crucial for developing regeneration-inducing strategies as mammalian hearts are limited in regenerative capacity. Exploring further our recently published optimized approach for increasing the single cell RNA sequencing (scRNA-seq) resolution specifically CMs, we have systematically evaluated transcription factors (TFs) defining regenerating zebrafish CMs. Here, after the scRNA-seq analysis, we observed a CM cycling cluster exclusively present in zebrafish injured hearts, which allowed us to identify potential TFs.

2026-09-01 | GSE280871 | GEO

Effects of Pharmacological Polyploidization in Human iPSC-derived Cardiomyocytes

Project description:Cell polyploidization, an increase in cellular DNA content without cytokinesis, is closely linked with aspects of cellular function in various tissues and is a defining characteristic of postnatal heart development in many species. However, investigation into how polyploidy affects cardiomyocytes (CMs) has been limited. Despite these challenges, CM polyploidy has been directly shown to attenuate proliferation in zebrafish CMs and diploid CM abundance correlates with recovery following coronary artery ligation in mice, highlighting the importance of understanding this biological process in CMs. In this study, we generated polyploid hiPSC-CMs via inhibition of Aurora Kinase B and found this results in increased cell size, reduced baseline cycling rates and responsiveness to mitogenic stimuli, affected the overall transcriptome and rates of transcription and translation, and altered CM Ca2+ handling. Our work suggests that CM polyploidy may not be just an outcome of CM maturation, but rather it serves a functional purpose. Further examination of the differences between diploid and polyploid hiPSC-CMs can expand our understanding of postnatal CM development and how polyploidy impacts CM growth and maturation.

2025-08-23 | GSE293429 | GEO

Nanostring microRNA microarry analysis of p53 and Mdm2 knockout mouse hearts compared to vehicle-injected negative controls

Project description:Adult cardiomyocytes (CM) are terminally differentiated cells with minimal regenerative capacity, making cardiac tissue particularly vulnerable to injury. Thus, defining the roadblocks responsible for adult CM cell cycle arrest lies at the core of developing therapies to regenerate myocyte loss following injurious events such as myocardial infarction. We have previously shown that inactivating the p53/Mdm2 tumor suppressor circuitry, specifically in the heart (using the Cre-loxP recombination system of bacteriophage P1), can allow differentiated CMs to regain proliferative capacity, through an upregulation of factors involved in cell cycle re-entry. These factors are repressed in quiescent CMs, in part through the action of microRNAs (miRNAs). Notably, knockout of either p53 or Mdm2 individually was insufficient to promote CM proliferation. Therefore, we hypothesized that inactivation of p53/Mdm2-regulated miRNAs could promote the expression of cell cycle activators and induce proliferation of adult murine CMs. To identify miRNAs regulated by both p53 and Mdm2, total miRNA expression profiles from cardiac specific p53/Mdm2 double knockout (DKO) mouse hearts were compared with those from cardiac-specific single knockouts (p53KO and Mdm2KO), and vehicle-injected controls using the Nanostring nCounter mouse miRNA expression assay. This revealed a profile of 11 significantly downregulated miRNAs in the proliferative DKO hearts (versus vehicle-injected control), that were enriched for mRNA targets involved in cell cycle regulation. In vitro studies have demonstrated that knockdown of these 11 miRNAs in neonatal rat cardiomyocytes can increase the occurrence of cytokinetic events. Ultimately, we aim to inject antagomirs targeting these miRNAs into animals post-myocardial infarction to determine the effect of p53/Mdm2-regulated miRNAs on heart function and CM proliferation in vivo.

2017-03-22 | E-MTAB-5531 | biostudies-arrayexpress

YAP rejuvenates cardiomyocytes by changing mitochondrial substrate utilization

Project description:Postnatal cardiomyocyte (CM) maturation, marked by a metabolic transition from glycolysis to fatty acid oxidation, impedes adult CM proliferation and heart regeneration. Our research reveals that Hippo-YAP signaling facilitates CM cell cycle re-entry by reducing lipid utilization in CMs, thereby preserving mitochondrial homeostasis, and promoting CM rejuvenation. On the other hand, overloaded fat by a maternal high-fat diet significantly enhances fatty acid oxidation and maturation in neonatal CMs, counteracting YAP-mediated rejuvenation effects. Through metabolomic and transcriptomic analyses, we discovered that YAP-induced mitochondrial substrate utilization change predominantly depends on reducing Cpt1b activity. Additionally, we identified Mef2 as a crucial activator for CM maturation, which is inhibited upon YAP overexpression, leading to decreased Cpt1b levels in CMs. Our results highlight the heterogeneity and adaptability of neonatal CM energy metabolism and establish YAP as a key regulator of CM substrate utilization. Furthermore, we elucidate a mechanistic framework by which YAP reverses metabolic maturation in cardiomyocytes, thereby facilitating heart regeneration. This insight advances our understanding of metabolic remodeling in heart regeneration and the therapeutic potential of YAP.

2026-04-21 | GSE262046 | GEO

Novel gene therapy CM-YAPon protects the mouse heart from myocardial infarction - MI

Project description:Myocardial infarction (MI), which affects about 3 million people globally each year, permanently damages the heart and reduces cardiac function1. Recent studies have indicated that activating YAP in cardiomyocytes (CMs) promotes cardiac regeneration and mitigates pathological remodeling in mouse and pig MI models2,3. To precisely control YAP activity in vivo and encourage its clinical application, we developed an adeno-associated virus 9 (AAV9)-based therapy, termed CM-YAPon, which triggers YAP activation in CMs upon exposure to a small molecule LMI070. One dose of LMI070 in mice induced a transient expression of active YAP (YAP5SA), which was subsequently degraded within a week. Consistent with earlier findings, YAP activation after injury improved cardiac function. Interestingly, administering a single LMI070 injection two weeks before MI provided lasting cardioprotection, which diminished by four weeks after the transient YAP activation, by reducing non-CMs cell death and enhancing cardiac function. Taken together, our novel gene therapy CM-YAPon presents a promising avenue for developing protective strategies against MI-induced cardiac injury.

2025-09-30 | GSE293327 | GEO

Novel gene therapy CM-YAPon protects the mouse heart from myocardial infarction - 3 day post-LMI

2025-09-30 | GSE293209 | GEO

Novel gene therapy CM-YAPon protects the mouse heart from myocardial infarction - Virus Test

2025-09-30 | GSE270256 | GEO